These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15816402)

  • 1. [Chemoprevention of prostatic cancer].
    Eschwege P
    Prog Urol; 2003 Nov; 13(5 Suppl 2):1262-7. PubMed ID: 15816402
    [No Abstract]   [Full Text] [Related]  

  • 2. 'Urology: Today's Advances, Tomorrow's Clinical Practice', Cannes, November 2003. Current thinking in prostatic diseases: insights into dual 5alpha-reductase inhibitor therapy in BPH and prostate cancer.
    Fitzpatrick JM
    Prostate Cancer Prostatic Dis; 2004; 7(2):91-2. PubMed ID: 15175660
    [No Abstract]   [Full Text] [Related]  

  • 3. Open to debate. The motion: prevention of prostate cancer with a 5alpha-reductase inhibitor is feasible.
    Roehrborn CG; Lotan Y; Tubaro A; de Nunzio C
    Eur Urol; 2006 Feb; 49(2):396-400. PubMed ID: 16455190
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate cancer chemoprevention: current status and future prospects.
    Gupta S
    Toxicol Appl Pharmacol; 2007 Nov; 224(3):369-76. PubMed ID: 17189645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer chemoprevention: more than meets the eye.
    Gomella LG
    Can J Urol; 2010 Jun; 17(3):5148. PubMed ID: 20566004
    [No Abstract]   [Full Text] [Related]  

  • 6. Current and future status of prostate cancer chemoprevention.
    Fujimoto N; Nomura M; Matsumoto T
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):59-71. PubMed ID: 16375645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current prospects for the chemoprevention of prostate cancer.
    Kirby RS; McNicholas TA; Fitzpatrick JM
    BJU Int; 2010 Sep; 106(6):751-3. PubMed ID: 20795995
    [No Abstract]   [Full Text] [Related]  

  • 8. Mechanisms of selenium chemoprevention and therapy in prostate cancer.
    Nadiminty N; Gao AC
    Mol Nutr Food Res; 2008 Nov; 52(11):1247-60. PubMed ID: 18727008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of disease: Prostate cancer--a model for cancer chemoprevention in clinical practice.
    Canby-Hagino ED; Thompson IM
    Nat Clin Pract Oncol; 2005 May; 2(5):255-61. PubMed ID: 16264961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of chemoprevention for prostate cancer development: experimental in vivo approaches to chemoprevention.
    Shirai T
    Pathol Int; 2008 Jan; 58(1):1-16. PubMed ID: 18067635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How statins may increase prostate cancer.
    Goldstein MR; Mascitelli L; Pezzetta F
    Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):459. PubMed ID: 18268131
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of prostate cancer. Part 1: chemoprevention.
    Sooriakumaran P
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):419-25. PubMed ID: 16503858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prostate Cancer Prevention Trial and the future of chemoprevention.
    Thompson IM; Tangen CM; Lucia MS
    BJU Int; 2008 Apr; 101(8):933-4. PubMed ID: 18353157
    [No Abstract]   [Full Text] [Related]  

  • 14. Epidemiologic musing on statin drugs in the prevention of advanced prostate cancer.
    Platz EA
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2175-80. PubMed ID: 17982117
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer.
    Adolfsson J
    Eur Urol; 2009 May; 55(5):1074. PubMed ID: 19200637
    [No Abstract]   [Full Text] [Related]  

  • 16. [Relevance of chemoprevention from PCPT trial].
    Irani J
    Prog Urol; 2008 Apr; 18 Suppl 3():S63-5. PubMed ID: 18455087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on prostate cancer chemoprevention.
    Lowe JF; Frazee LA
    Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoprevention of prostate cancer through dietary agents: progress and promise.
    Syed DN; Khan N; Afaq F; Mukhtar H
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2193-203. PubMed ID: 18006906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How should we advise patients about the chemoprevention of prostate cancer?
    Kirby RS; Fitzpatrick JM
    BJU Int; 2005 Aug; 96(3):231-2. PubMed ID: 16042705
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer.
    Orvieto M; Eggener S
    Eur Urol; 2009 May; 55(5):1073-4. PubMed ID: 19200640
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.